Depression represents the first cause of disability in the world, according to the WHO. Despite multiple drug classes and dozens of approved therapies, there is a high unmet need for additional, novel treatments that are safe, effective, rapid acting, and well-tolerated to improve the lives of people living with major depressive disorder (MDD).
View resources
We believe that REL-1017 has the potential to treat MDD safely, effectively, more quickly and with greater tolerability than has previously been thought possible. We are advancing REL-1017 to phase 3 as an adjunctive treatment for MDD while planning additional indications.
Learn more about our product development
Ours is a team of experienced professionals committed to improving the lives of those living with MDD, and potentially other CNS diseases. As we bring our lead program forward to registration phase 3 studies, we are expanding our team accordingly.
Meet our team
We are a late-stage pharmaceutical company registered and traded on the NASDAQ stock exchange under RLMD. Learn more from recent press releases and presentations.
View investors section
